NCT03448666 2024-09-23
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
Phase 2 Withdrawn
European Institute of Oncology
Uppsala University Hospital
Copenhagen University Hospital at Herlev